Related Experiment Video
Updated: Jul 6, 2026

Three-dimensional Alginate-bead Culture of Human Pituitary Adenoma Cells
Published on: February 18, 2016
RGD-FasL induces apoptosis of pituitary adenoma cells
Lukui Chen1, Guohong Zhuang, Wenzhu Li
1Department of Neurosurgery, Zhongshan Hospital, Xiamen University, Xiamen, Fujian 361004, China. neuro_clk@hotmail.com
Abstract:
This study was to investigate the cytotoxic effects on pituitary adenoma cell lines GH3/MMQ/AtT20 induced by RGD-FasL and the underlying mechanism. Fas/DcR3 mRNAs were detected by RT-PCR and their surface expressions were measured by flow cytometry. Cytotoxicity exerted by RGD-FasL on tumor cells was measured with MTT assay and the induced apoptosis was determined by agarose gel electrophoresis. The cell cycle and apoptosis was assessed by flow cytometry with PI staining. The expressions of caspase8/9/3, Bcl-2, RANKL and JNK2 were detected by Western blotting. Approximately 13.7% of GH3 cells, 25.5% of MMQ cells, 22.2% of AtT20 cells express Fas, while 23.9% of GH3 cells, 24.1% of MMQ cells, 4.6% of AtT20 cells express DcR3. The cytotoxic effects of FasL/RGD-FasL on tumor cells were all taken in a dose-dependent manner. Cell lines MMQ/AtT20 showed the same sensitivity to RGD-FasL as to FasL, while cell line GH3 was less sensitive to RGD-FasL. The cell cycle analysis indicated that RGD-FasL could inhibit cells in G0/G1 phase and G2/M phase. In MMQ and AtT20 cells treated with RGD-FasL, the AI was not significantly different from that treated with FasL, while in GH3 cells treated with RGD-FasL, the AI was lower than that treated with FasL. The expressions of caspase-8/9/3, RANKL and JNK2 were increased while that of Bcl-2 was decreased after treatment with RGD-FasL, suggesting that RGD-FasL induces apoptosis through caspase activation. We concluded that RGD-FasL could possibly be considered as a novel therapeutical candidate for the treatment of pituitary adenomas.
Insights
RGD-FasL demonstrates cytotoxic effects on pituitary adenoma cells by inducing apoptosis through caspase activation. This suggests RGD-FasL as a potential novel therapeutic for pituitary adenomas.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Pituitary adenomas are common tumors.
- Targeted therapies are needed for pituitary adenoma treatment.
- Fas ligand (FasL) and its receptor Fas are involved in apoptosis.
Purpose of the Study:
- To investigate the cytotoxic effects of RGD-FasL on pituitary adenoma cell lines (GH3/MMQ/AtT20).
- To elucidate the underlying molecular mechanisms of RGD-FasL-induced cytotoxicity.
Main Methods:
- Reverse transcription-polymerase chain reaction (RT-PCR) for Fas/DcR3 mRNA.
- Flow cytometry for surface protein expression and cell cycle analysis.
- MTT assay for cytotoxicity and agarose gel electrophoresis for apoptosis.
- Western blotting for apoptosis-related proteins (caspases, Bcl-2, RANKL, JNK2).
Main Results:
- RGD-FasL exhibited dose-dependent cytotoxicity against pituitary adenoma cell lines.
- MMQ and AtT20 cells showed sensitivity to RGD-FasL similar to FasL, while GH3 cells were less sensitive.
- RGD-FasL induced cell cycle arrest and apoptosis.
- Increased expression of caspase-8/9/3, RANKL, and JNK2, with decreased Bcl-2 expression, indicated caspase-dependent apoptosis.
Conclusions:
- RGD-FasL induces apoptosis in pituitary adenoma cells via caspase activation.
- RGD-FasL shows promise as a novel therapeutic candidate for pituitary adenomas.
Related Concept Videos
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
The Ras Gene
Ras is a superfamily...
GPCRs Regulate Adenylyl Cylase Activity
Two...
The Extrinsic Apoptotic Pathway
